Drugs / MK-2010
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06843447 | Apr 2025 → Mar 2029 expected | ovarian carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07793942 | Oct 2026 → Sep 2028 expected | cancer | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07785609 | Oct 2026 → Sep 2031 expected | cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-2010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07793942 ↗ |
| Route | Intravenous | “IV infusion on Day 1 of every 3-week cycle” NCT06843447 ↗ |